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Estimation of local production and metabolism of angiotensin I in
hypertensive patients. P. Admiraal, F. Derkx, M. Schalekamp, Depart-
ment ofInternal Medicine I, University Hospital Dijkzigt, Rotterdam,
The Netherlands. To explore the possibility of measuring the rate of
metabolism and production of Ang I, '251-labelled Ang 1 was given by
constant i.v. infusion (2 to 4 x 106 cpm per mm for 20 mm) to five
hypertensive patients. After reaching steady state (8 mm), samples
were drawn from the aorta, renal veins and antecubital vein. Labelled
and unlabelled Ang I and II were isolated from plasma, separated by
HPLC and quantified in the gamma counter or by radioimmunoassay.
Plasma renin activity (PRA) at physiological pH and plasma volume
(PV) were also measured. The metabolic clearance rate (MCR) of
'251-Ang I, calculated as infusion rate divided by the plasma level of
'251-Ang I in the antecubital vein, was 15.9 5.4 (mean SD) liter/mm.
The production rate of Ang 1, calculated as MCR times the plasma level
of Ang I, was 4 to 5 times higher than the production rate calculated as
PRA times PV. In the kidneys 82.4 3.8% and in the arm 52.0 20.8%
of the arterially delivered Ang 1 was removed, whereas the levels of
unlabelled Ang I in the renal and antecubital veins were not different
from those in the aorta. Transit times through the kidneys and the arm
are too short for PRA to compensate for the rapid removal of Ang I. We
conclude that most of the circulating Ang I is not systemically but
locally produced.
Increased conversion of a glomerular polyanion affecting plasma factor
in minimal change nephrotic syndrome. W.W. Bakker, W.H.J. van
Luzjk, iF.W. Bailer, Departments of Pathology and Pediatrics, Uni-
versity Hospital, Groningen, The Netherlands. Circulating factors are
thought to play a role in the pathogenesis of increased glomerular
permeability in minimal change nephrotic syndrome (MCNS). How-
ever, the nature of one or more putative factors is uncertain. We
recently purified a vasoactive plasma factor (mol weight 100 kD) from
normal human (pool) plasma, which was able to affect glomerular
sialoglycoproteins in vitro as well as anionic sites of the GMB following
perfusion of the normal rat kidney ex vivo. To study the relative amount
of this factor (100 KF) in the circulation, we assayed 100 KF in plasma
and urine samples of various patients and control persons using affinity
purified rabbit-anti-lOO KF IgO with rocket electrophoresis (Laurell).
The patients included untreated MCNS in relapse (N = 7) proteinuria
1.5 to 5.0 g/24 1w; proteinuric subjects with other forms of glomerulo-
nephritis, that is, IgA nephropathy, MPGN, congenital glomerulopathy,
and membranous glomerulopathy (N = 9); proteinuria 1.6 to 7.0 g124 hr.
Also plasma samples from healthy donors were studied (N = 10). In
addition to the 100 KF titer assays, samples were also tested for
vasoactivity in vivo using a standard vascular permeability test in the
rat skin. The results show a mean decrease of titers in plasma samples
of patients with MCNS versus ON or control donors (P < 0.01; titers
returned to normal control values in remission after corticosteroid
treatment). The mean drop of 40% in MCNS plasma versus ON plasma
(10.3 3.4 mg/mI GN vs. 6.1 2.0 mg/mI MCNS P  0.01), was
associated with a relative 100 KF urinary increase of 365% in MCNS
(200 75 tg/ml ON vs. 930 300 g/ml MCNS, P  0.05), suggesting
a relatively high turnover of 100 KF in MCNS plasma. In contrast,
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while the vasoactivity of the same plasma samples was increased in
proteinuric subjects versus control donors (P  0.05), the mean
vasoactivity in the urine samples of MCNS subjects was significantly
decreased as compared to that of samples from ON subjects (mean
vasc. perm. index: SI 3.5, ON vs. 13.0 1.4, MCNS, P  0.05).
These data support the idea that increased turnover of 100 KF occurs in
MCNS, leading to release and/or altered metabolism of vasoactive
molecules. The potential of this altered IOOKF activity to affect the
filtration barrier in vivo in this condition remains to be established.
Paradoxical high lithium clearance (CLI) in Bartter's syndrome (BS).
W.H. Boer, R.J. Hene, H.A. Koomans, E.J. Dorhout Mees, Depart-
ment of Nephrology, University Hospital, Utrecht, The Netherlands.
As indicated by free water clearance studies, the abnormalities in renal
Na handling in BS consist of a primary defect in Na reabsorption in the
diluting segment and, to maintain Na balance, a secondary fall in Na
delivery to this site. Consequently, one would expect CLI, advanced as
a quantitative index of Na output from the proximal tubules, to be low
in BS. We studied CLI in five patients with BS. Simultaneously, we
measured the maximum urine flow during water diuresis (Vmx), an
index of Na delivery to the diluting segment. In three patients, studies
were repeated during chronic converting enzyme inhibition (CEL) with
enalapril, which reversed hypokalemia (pK: 2.4 —* 3.9 mmol/liter).
BSN=5 ControlsN=18
CLI/GRF % 36.2 (34. 1—39.4) 31.2 (23.4—39.0)
V,,ax/OFR % 11.3 (9.9—13.5) 15.3 (12.5—18.0)
CLI/V=ax 3.23 (2.60—3.97) 2.12 (1.71—2.53)
(BS: mean, range between parentheses; controls: mean, 95% confi-
dence intervals between parentheses; Na excretion in BS and controls
was similar).
Surprisingly, values for CL/OFR were in the high normal range in all
patients with BS. As expected, Vmx/OFR was in the low normal range.
The ratio between CLI and V,, was markedly elevated. During CEI,
CLI/GFR fell in all three patients with BS (from 34 to 19%, 39 to 24% and
36 to 22%, respectively), whereas VmaX/OFR did not change. Conse-
quently, the ratio between CLI and Vma, normalized, falling from 3.38(mean) to 1.79. Conclusion: CLI seems to overestimate distal Na
delivery in BS. Suppression of postulated Li reabsorption in Henle's
loop (hypokalemia-induced rise in prostaglandin synthesis ?) could be
the cause, since CEL (not or slightly reducing CL in normal subjects),
corrected hypokalemia and strongly enhanced tubular Li reabsorption
in BS. These observations, by pointing to possible Li transport in
Henle's loop, suggest that CL, may not be a correct index of Na and
H20 delivery from the proximal tubules in man.
Cytomegalovirus (CMV) infection and disease after renal transplanta-
tion in patients on cyclosporine and prednisone. F.H. Bosch, A.J.
Hoitsma, H.P. Janssen, A.M. van Loon, R.A.P. Koene, Departments
of Nephrology and Medical Microbiology, University Hospital, Nijme-
gen, The Netherlands. Most studies on the incidence of CMV infection
and CMV disease have been performed with azathioprine as the basic
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immunosuppression. We have performed a prospective study in 175
patients in whom the CMV status before transplantation was known
and who received cyclosporine after transplantation. CMV antibodies
in serum (1gM, IgG, igA) and CMV early antigen in urine were
determined at regular intervals during the first six months after trans-
plantation. Viral cultures of urine were also included. Before transplan-
tation 107 patients (61%) were seropositive and 68 (39%) seronegative.
CMV infection occurred in 68 seropositive (63%) and in 22 seronegative
(32%) patients (P < 0.001). CMV disease occurred in 10 of 68 seropos-
itive and in 14 of 22 seronegative patients who became infected (P <
0.001). The most important manifestations of CMV disease were fever
of unknown origin and leukopenia. There was only one patient with
CMV pneumonitis. He responded to treatment with gancyclovir
(DHPG). In the group with CMV infection there was an increased
occurrence of rejection (60% in infected, vs. 27% in non-infected
patients; P <0.001). However, in the majority of patients (41 of 54) the
rejection preceded the CMV infection. CMV infection did not lead to a
decreased graft survival rate. There was no close time relationship
between the onset of clinical symptoms of CMV disease and the
laboratory confirmation of CMV infection. We could not identify a
subgroup of patients at risk for severe CMV disease. Thus, seronega-
tive patients run an increased risk of overt CMV disease when they
develop CMV infection. Furthermore, the course of CMV infection
during cyclosporine treatment appears to be rather benign and does not
affect graft survival. Our results do not support the policy to deny a
kidney from a seropositive donor to a seronegative recipient.
Genetics of experimental lupus nephritis: Influence of non-H-2 related
factors on susceptibility for renal involvement in murine chronic graft-
versus-host disease. iA. Bruzjn, E.H. van Elven, WE. Corver, M.
Oudshoorn-Snoek, G.J. Fleuren, Department of Pathology, Leiden
University Hospital, Stichting Samenwerking De(ftse Ziekenhuizen,
and The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Genetic influence on renal involvement was studied in murine chronic
graft-versus-host disease (GvHD), which is a model for human systemic
lupus erythematosus (SLE). GvHD was induced in (C57BL/IOxDBA/
2)F1 and in (Bl0.SxDBA/2)Fl hybrids by injections of DBA/2 lympho-
cytes. All animals developed GvHD. Whereas all (BIOxDBA/2)Fl
hybrids developed renal disease and proteinuria, only 54% of the
(B10.SxDBA/2)Fl did so. The type of renal disease was comparable in
both strains, that is, immune complex glomerulonephritis with deposi-
tion of antibodies and complement in glomeruli. To investigate whether
H-2 haplotype or other factors such as non-H-2 genetical parameters
determine the susceptibility for renal involvement in GvHD.
(BIOxBIO.S)FIxDBA/2 mice were produced, and separated into H2t/d
and H-2' groups by allotyping. In these two populations, susceptibility
for renal disease in the course of GvHD was not different, indicating
that the H-2 is not the deciding genetical region. We therefore conclude
that factors not linked with H-2 exert a major influence on susceptibility
for GvHD-related renal disease in these mice. Further studies are
indicated to determine more specifically the genetic regions that deter-
mine susceptibility for renal pathology during SLE in man and experi-
mental animals.
Hantavirus nephropathy (HVN) in Belgium and The Netherlands. J.
Clement, M. Koolen, A. Lefei're, R. Verhagen, G. van der Groen,
Military Hospital Brussels, Belgium, and Groat Ziekengasthuis, 's
Hertogenbosch, The Netherlands. HVN is now a well recognized cause
of acute renal failure caused by Hantavirus (HV), a hemorrhagic fever
virus with a probable worldwide distribution and which is transmitted to
man by wild rodents. The first Dutch "wild-life" human case, recorded
in May 1986, is described. Retrospective serologic diagnosis was
secured by an unequivocal rise in specific anti-HV 1gM and lgG
immunofluorescent antibodies, confirmed by more specific enzyme
immunoassay and Western Blot techniques. Clinical features of the
Dutch case (peak serum creatinine 9.98 mg%, peak proteinuria 5 g/liter,
duration of impaired renal function 17 days) are comparable with those
found in a series of seven previously described Belgian cases. Medul-
lary hemorrhages and a minimal patchy interstitial nephritis were the
characteristics seen on a total of three kidney biopsies. All patients
lived in or near forested regions. In the 1986 to 1988 period, a total of
322 wild rodents were captured around the habitats of proven human
cases of HVN. Evidence of HV infection in rodents, that is, IgG
seropositivity and/or the presence of HV antigen in the lungs was
demonstrated in 47 (14.5%) animals. A much higher degree of rodent
infection, however, was demonstrated in Chimay, a forested area where
in the late spring of 1986 a cluster of four human HVN cases has been
described. In this locality 45 out of 134 rodents (33.5%) captured in June
1986 showed signs of a HV infection. The degree of contact with HV in
a standard Belgian population without symptoms is low, as appeared
from a blood bank serosurvey, whereby 287 out of 21,435 sera (1.33%)
showed the presence of specific anti-HV lgG immunofluorescent anti-
bodies. The diagnosis of HVN is warranted in viral forms of ARF after
a possible contact with rodents.
Association of segmental crescentic glomerulonephritis (SCGN) with
autoantibodies directed against different lysosomal enzymes. J. W. Cohen
Tervaert, R. Goldschmeding, J.D. Elema, M. tan der Giessen, P.C.
Li.'nhurg, (j.K. van der He,n, C.G.M. Kallenberg, Department of
Internal Medicine, University Hospital Groningen, and Central Labo-
rotary of tile Bloodtransfusion Service, Amsterdam, The Netherlands,
SCGN is frequently found in Wegener's granulomatosis (WG), one of
the systemic vasculitides associated with antineutrophil cytoplasmic
antibodies (ANCA), but may also occur idiopathically. To test the
hypothesis that SCGN is part of the spectrum of systemic vasculitides
we evaluated the clinical and serological data of 28 consecutive patients
with SCGN with or without systemic vasculitis biopsied between June
1984 and March 1988. Patients with SCGN as part of anti-GBM
nephritis. SLE nephritis and Henoch Schönlein purpura (N = 7) were
excluded. The presence of ANCA and other autoantibodies to lyso-
zomal enzymes was tested with a "sandwich" ELISA in which mouse
monoclonal antibodies directed against the ANCA antigen, myeloper-
oxidase (MPO) and elastase were used as catching antibodies. Nine
patients had biopsy proven WG, 13 patients were clinically suspected of
WG, and three patients had idiopathic SCGN. The remaining three
patients had SCGN secondary to an infectious origin. Antibodies to
lysozomal enzymes were found in 25 out of 28 patients (Table).
Biopsy Clinically SCGN of
proven suspected Idiop. infectious
WG WG SCGN originN—9 N=-13 N=3 N=3
ANCA 9 Il 1 0
Anti-MPO 0 2 2 0
Anti-elastase 0 0 0 0
in sera from patients with SLE nephritis (N II), lgA nephropathy (N
12), MPGN (N = II), other forms of SCGN (see above, N = 7) and
from normal donors these autoantibodies could not be detected. We
conclude that SCGN of non-infectious origin is associated with either
ANCA or anti-myeloperoxidase antibodies. These antibodies may be an
early marker of systemic vasculitis. Our data suggest that idiopathic
SCGN is part of the spectrum of systemic vasculitides.
Glomerulonephritis and proteinuria by a single monoclonal autoanti-
body against gp330. E. de Heer, A. M. Deelder. P.C. W. Hogendoorn,
G.J. Fleuren, MR. Dalia, L.A. tan Es, Department.s of Pathology,
Parasitologv and Nephrology. University Hospital and Medical Fac-
ally, Leiden, The Netherlands. B-cells obtained from Lewis rats with
active Heymann's nephritis (HN) were fused with SP 2/0 mouse
myeloma cells. Clones producing monoclonal antibodies (MoAb) to
brush border antigens were identified both by ELISA and immunoflu-
orescence (IF). Two rat/mouse clones, 3D9B and 5B8C that secreted rat
IgG2 antibodies, were propagated further in vitro. Immunoprecipita-
tion of crude brush border antigens and HPLC analysis showed that
clone 3D9B only precipitated a 330 kD molecule while 5B8C precip-
itated a 600 kD, a 330 kD and a 300 kD molecule. Immuno-E.M.
studies demonstrated marked differences in renal binding characteris-
tics of these two clones. Passive transfer of MoAb from clone 3D9B
produced immediate (within I hour) linear glomerular binding, but
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failed to produce functional renal damage within seven days. Injection
of MoAb of clone 5B8C, however, caused granular glomerular deposits
within one hour, subepithelial immune aggregates within six days and
antibody deposition on the brush border within seven days. Ascites was
obtained by injecting 5 x IO rat/mouse hybridoma cells into pristane-
primed, sublethally irradiated, mice and nude rats. Only ascites pro-
duction of clone 5B8C in rats caused glomerulonephritis as detected by
IF, EM, immuno-EM and proteinuria. This study shows that a single
monoclonal autoantibody to gp330 is able to induce passive glomerulo-
nephritis and proteinuria.
Immunocytology of urinary sediments in the diagnosis of rejection of
renal allografts. Ph.M.M, Dooper, M.J.J.T. Bogman. C.N. Maass,
G.P. Vooys, R.A.P. Koene, Departments of Pathology and Medicine,
Division of Nephrology, University Hospital, N,jmegen, The Nether-
lands. Urinary cytology has been used to monitor patients with renal
transplants, but it has not been studied whether the increase in
HLA-DR expression on tubular epithelial cells (TEC) and T lympho-
cytosis, as observed in renal biopsies and fine needle aspirates of
patients with rejection, is also reflected in the cells appearing in the
urine. Therefore cytocentrifuge preparations of 65 urinary sediments of
kidney allograft recipients were incubated with monoclonal antisera
against T cell markers (Til, UCHLI) and HLA-DR, followed by
incubation with alkaline phosphatase-conjugated rabbit anti-mouse Ig
and color development with Fast Red and hematoxylin. Preparations
were examined without prior knowledge of clinical data. T lymphocy-
tosis and increased H LA-DR positivity of TEC were considered to
indicate rejection. Of 23 sediments (20 patients) with immunocytologi-
cal signs of rejection 19 correlated with clinical and/or histological signs
of rejection. Four patients had no clinical signs of rejection at the time
of positive cytology. In 42 urinary sediments (18 patients) no signs of
rejection were found and in only four of these the results were false
negative. In this study the sensitivity of the urinary immunocytology
was 83% and the specificity 90%. Experimental data suggest that
treatment with cyclosporine causes a decrease in MHC class 11 expres-
sion, implying that an increase of HLA-DR expression on TEC after
conversion to azathioprine treatment would not be diagnostic of rejec-
tion. In urinary sediments of 14 patients studied weekly from two weeks
before to four weeks after conversion we found in general no increase
of HLA-DR expression on TEC. Two of three patients with an increase
in HLA-DR expression on TEC together with T lymphocytosis devel-
oped a rejection while in the third patient no rejection occurred. We
conclude that immunocytological examination of the urinary sediment
is a useful and simple adjunct in the diagnostic monitoring of rejection.
Opposite effects of nitrendipine and enalapril on renal ANF response in
man. C.A. Gaillard, HA, Koomans, A.J. Rahelink, E.J. Dorhout
Mees, Department of Nephrologv, University Hospital, Utrecht, The
Netherlands. We investigated the effect of calcium entry blockade
(CEB) with nitrendipine (4 days: 20mg b.i.d.) and of converting enzyme
inhibition (CEI) with enalapril (4 days: 20 mg b.i.d.) on renal effects of
ANF(25 zg bolus followed by 0.03 g kg' min for 90 mm) in six
healthy men taking 300 mmol sodium daily. in the clearance study
without CEB or CEI, natriuresis rose from 239 38 to 605 137 mol/
mm (P < 0.05). During CEB natriuresis increased from 330 53 to 943
152 zmol/min (P < 0.05), and CEI from 236 22 to 344 39 tmol/
mm (NS). ANF induced a rise in maximal free water clearance, inulin
clearance, and in the excretion of multiple electrolytes except potas-
sium. Fractional lithium reabsorption fell. In general, these effects were
stronger during CEB and blunted during CEI. Para-aminohippurate
clearance tended to decrease during control study (NS), remained
constant during CEB, and decreased significantly when ANF was
infused during CE! (P < 0.05 vs. control). During treatment with CEB
and CEI mean arterial pressure (MAP) was lowered by, respectively, 3
mm Hg and 7 mm Hg. ANF had no additional effect on MAP except for
a short lasting drop during CEB. From these data we conclude that, in
healthy humans, the effects of ANF on natriuresis and renal sodium
handling are enhanced by CEB and blunted by CE!. The clinical
implication of these data might be that CEB can be used to enhance the
actions of endogenous ANF (heart failure), and CE! to attenuate action
of endogenous ANF (hyperfiltration).
The interaction between rat mesangial cells (MCs) and extracellular
matrix (ECM) in prolonged culture. J. Grond, M. Coffee, M. Kashga-
nan, R.B. Sterzel, Department of Pathology, University Hospital,
Groningen, The Netherlands; and Department ofMedicine, Section of
Nephrology, and Department of Pathology, Veterans Administration
Medical Center and Yale University School of Medicine, New Haven,
Connecticut USA. The present study examines the interaction of rat
MCs and ECM in prolonged (6 to 8 weeks) culture, where MCs grow
three-dimensionally in 'hillocks'. Hillocks consist of a core of ECM
with scattered stellate MCs surrounded by MCs of a fusiform pheno-
type. Short term (<2 weeks) cultures of MCs growing in two dimen-
sions were studied either at confluency or at sparse density for
comparison. MC growth was assessed by immunocytochemistry after
24 hours exposure to the thymidine analogue 5-bromo-2'-deoxyuridine
(BrdU, 50 g/ml medium). Small uninodular hillocks with a diameter
(mean I SD) of 0.29 0.07 mm, range 0.13 to 0.63 mm) in six cultures
per time point on millipore filters were studied. After four days of serum
starvation in resting medium with 0.5% fetal calf serum (FCS), MCs
were either kept in resting medium or switched to growth medium with
20% FCS for the subsequent four days. In resting medium, both
fusiform and stellate MC types showed a persistent low-level growth
activity with labeling indexes of 9 3% and 4 2% at day 5 (P <0.01),
and 5 2% and 3 2% at day 8 (NS), respectively. In growth medium,
BrdU labeling of fusiform MCs rose markedly to 39 9% at day 5 and
further to 54 6% at day 8 (P < 0.01 vs. day 5). In contrast, BrdU
incorporation of stellate MCs did not change when exposed to growth
medium (4 1% and 4 2% at day Sand 8, NS, respectively). Labeling
of central stellate MCs was independent of hillock size and the intensity
of immunostaining of BrdU-positive stellate and fusiform MCs was
similar. BrdU-positive fusiform MCs were found to grow in ECM
consisting predominantly of fibronectin, laminin, thrombospondin, and
collagen type IV. The stable population of stellate MCs was surrounded
by ECM with additional abundant collagen I and III. ln short term
culture, ECM was present only when MCs had reached confluency.
Confluent MCs continued BrdU incorporation in resting medium with
labeling indexes of 10 3% at day 5, and 5 2% at day 8 (P < 0.01).
respectively. In contrast, sparse MCs completely lacked ECM, and
BrdU labeling in resting medium was low at day 5 (2 1%) and very
rare at day 8 (0.3 0.3%, P < 0.01). The response to growth medium
of confluent MCs (36 7% labeled cells at day 5 and 49 6% at day 8)
was significantly stronger than that of sparse MCs (21 8% at day 5 and
30 4% at day 8, P < 0.01 at both days). In conclusion. MCs in culture
form a biomatrix governing resting MC proliferative activity and the
response to growth-inducing FCS-containing medium as a solid-phase
growth modulator. Such up- and down-regulating mechanisms may be
important in orchestrating MC proliferation and ECM formation in
progressive glomerular disease.
Blood group non-O males are at high risk of kidney graft failure.
G.F.J. Hendriks, E.P.M. v. Steenberge, 1.M.Th. Schreuder, D. Baum-
gartner. G.J. Wenting. W. Wein,ar, University Hospital Dykzigt, Rot-
terdam, The Netherlands. In 1977, Opelz and Terasaki showed that
blood group non-O male recipients of poorly HLA-A,B matched kidney
grafts are at high risk of graft failure. We wondered whether the
previous report could be confirmed in cyclosporine A treated patients,
and whether blood group non-O male recipients of H LA-DR mis-
matched kidney grafts are also at higher risk of graft failure. The study
group consisted of 146 renal transplant patients (75 males and 71
females) who received grafts in 1984 to 1987. Only first grafts were
analyzed. No beneficial effect of HLA-A,B matching was observed in
the total group of 71 females. The one year survival rate of HLA-A,B
well-matched (0 to I A,B mismatches) grafts was 83% versus 89% in the
poorly matched (2 to 4 A,B mismatches) group. In contrast, a beneficial
effect of HLA-A,B matching was observed in the group of 75 male
recipients. The one-year graft survival of 36 HLA-A,B well matched
grafts was 91% (N = 36) versus 65% (N = 39) in the poorly matched
group (P < 0.06). The red cell blood-group type of males did influence
the relation between matchgrade and graft outcome in a very significant
way. In blood group 0 males no correlation of HLA-A,B matching was
found (P > 0.4), whereas a highly significant effect was observed in
blood group non-O males. The one-year graft survival rate in 22 blood
group non-O male recipients of HLA-A,B well-matched grafts was 91%
versus 50% in the poorly matched group (N = 23, P < 0.005). This
phenomenon, the non-O male restricted immune responsiveness against
HLA-A,B mismatched antigens, was also valid for HLA-DR matching.
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The difference in one year graft survival between 17 HLA-DR matched
and 28 HLA-DR mismatched grafts transplanted into non-O male
recipients was 41% (P < 0.003). In blood group 0 males the one-year
graft survival rates of HLA-DR matched (N = 9) and HLA-DR
mismatched (N = 21) grafts were 89% and 87%, respectively. In
conclusion: Blood group non-O male recipients of poorly matched
(HLA-A,B and/or DR) kidney grafts are at high risk of graft failure.
Collaborative efforts should be made to provide them with HLA
well-matched grafts.
Omega-3 polyunsaturated fatty acids improve renal function in renal
transplant recipients treated with cyclosporin A. J.J. Homan van der
Heide, H.J.G. Bib, A.M. Tegzess, A.J.M. Donker, University of
Groningen and Free University of Amsterdam, The Netherlands.
Cyclosporin A (CsA)-induced renal dysfunction is the most frequent
and clinically important adverse effect in renal transplantation. Animal
studies have shown that dietary fish oil supplements containing omega-3
poly-unsaturated fatty acids (w-3 PUFA's) protect against CsA neph-
rotoxicity. In a double-blind controlled study we investigated the effect
of Super EPAR (Pharmcaps UK; daily 6 grams containing 30% 20:3 -3
and 20% 22:5 a-3) versus corn oil (daily 6 grams containing 50% 18:2
o-6) in renal transplant recipients, all treated with 10 mg prednisolone
and CsA. Patients were admitted to the study at least nine months after
grafting, their renal function being stable for three months prior to the
start of the trial. Before fish or corn oil supplementation was started
glomerular filtration rate (OFR) and effective renal plasma flow (ERPF)
were measured as are blood pressure (MAP), whole blood CsA through
levels (CsAL; monoclonal RIA Sandoz, BasIc, Switzerland) and lipid
profile. The variables were measured again after three months, during
which period diet and medication, including the CsA dose (4.6 mg/kg!
day; N = 14), were kept constant.
Fish oil N = 10) Corn oil (N = 4)
Pre Post Pre Post
GFR 57 4.7 69 55 66 7.8 65 8.0
ml/min/1.73 m2
ERPF 240 16.4 272 23.8 245 7.8 243 27.5
ml/min/1.73 m2
MAPmmHg 107±2.6 98±2.7a 113±3.9 112±4.1
CsAL ng/ml 96 6.1 98 5.3 100 7.6 81 3.4
a p < 0.05 (Wilcoxon test); all values are reported as mean 5EM.
In contrast to corn oil-treated patients, all fish oil-treated patients
showed an increase in GFR and a decrease in MAP. Fish oil-treated
patients showed no changes in total cholesterol and HDL-chol while
triglyceride levels decreased significantly. Further studies are war-
ranted to investigate whether o-3 PUFA supplementation protects
against acute postoperative and long-term irreversible CsA-induced
renal dysfunction.
The antihypertensive effect of a 5 day infusion of atrial natriuretic
peptide (ANP) in man. W.M.T. Janssen, D. de Zeeuw, G.K. van der
Hem, P.E. de Jong, Division of Nephrology, State University Hospital,
Groningen, The Netherlands. To date only relative short-term ANP
infusions have been evaluated in man; at high doses salidiuretic as well
as blood pressure lowering effects are observed, whereas at low (more
physiological) doses only salidiuretic effects are present. We therefore
studied the effects of aS day, very low dose (0.2 g/min) ANP infusion
on mean arterial pressure (MAP) and sodium balance (NaB) in six
essential hypertensives (EH) in metabolic ward conditions. Patients
were without medication for six weeks, in balance on 150 mmol!day
sodium intake, and kept bedrest during three equilibration, three
control, five ANP infusion, and three recovery days. MAP and pulse
were measured every IS minutes, ANP and NaB every four hours (hr).
Table shows the 24 hr mean SEM.
Control ANP 1st 5th-day Recovery
ANP pg/mI 49 10 114 19 106 19 52 14
MAPmmHg 104±3 101±3 92±2 98±4
Pulse bpm 64 4 69 4 72 4 67 4
NaB mmol 0 10 —70 II —72 IS —3 52
ANP caused an immediate rise in sodium excretion, levelling after 24
hours (range NaB: —32 to —139 mmol). MAP only started to fall after
12 hr to level off after 40 hr. The fall in MAP was 10.9 1.0% (7.7 to
13.8%). Plasma ANP levels and NaB recovered to baseline within 24 hr,
whereas MAP slowly returned towards baseline values over three days.
The data show that in EH chronic low-dose ANP infusion causes a
negative sodium balance followed by a slower decrease in blood
pressure with a new equilibrium after about two days. Thus, ANP-like
substances may become useful antihypertensive drugs.
Colloid osmotic pressure and renal function in the young analbumine-
mic rat. J.A. Joles, N. Willekes-Koolsch,jn, B. Braam, H.A. Koomans,
E.J. Dorhout Mees, Department of Nephrology, Utrecht University,
The Netherlands. Colloid osmotic pressure (COP) was measured using
a strain-gauge oncometer in plasma and interstitial (subcutaneous wick)
fluid in young Nagase Analbuminemic rats (NAR) and control Sprague-
Dawley rats (SDR; 6 males and 6 females of each strain). GFR and
ERPF were measured using plasma sampled 60 minutes after a single
shot of respectively 51Cr-EDTA and '251-hippuric acid. At a body
weight of 330 g plasma COP had increased to 15.8 mm Hg in the male
NAR as compared to 19.8mm Hg in the controls (P <0.01). In the same
groups at this body weight the interstitial COP was 5,3 mm Hg in the
NAR and 9.6mm Hg in the SDR (P < 0.01). In the female NAR plasma
and interstitial COP were 2 to 3 mm Hg lower than in the controls. Thus
the transcapillary COP gradient was very similar in both strains. Plasma
and extracellular fluid volumes measured by isotope dilution and blood
pressure measured with a tail cuff were similar in both strains.
Strain
Males Females
SDR NAR SDR NAR
GFR 0.98 0.06 0.85 0.04 0.99 0.04 0.85 o.o4
N = 24,
mi/mm!
/00 g
ERPF 1.72 0.17 1.56 0.11 2.05 0.14 1.64 0.08
N = 12,
mI/mm!
100 g
GFR/ERPF 0.59 0.02 0.54 0.01 0.54 0.02 0.53 0.01
N = 12
Kidney 0.42 0.01 0.30 0.Ola 0.40 0.02 0.32 o.ol
weight
N = 6, g
a P < 0.05 as compared to SDR
The renal function (related to body weight) was slightly reduced in NAR
as compared to SDR, but the filtration fraction was similar. In relation
to kidney weight, however, renal perfusion and filtration were high in
NAR. The low plasma COP in NAR theoretically enhances capillary
and glomerular filtration. This is probably averted by respectively a
decrease in interstitial COP and an increase in preglomerular vasocon-
striction.
Donor-specific lysis of human kidney epithelial cells of proximal tubulur
origin by renal allograft-infiltrated lymphocytes. A.M.M. Miltenburg,
M.E. Mejjer-Paape, M.R. Daha, L.A. van Es, F.J. van der Woude,
Department of Nephrology, University Hospital, Leiden, The Nether-
lands. The study of in situ mechanisms of allograft rejection has defined
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a role for graft infiltrating cells (GIC) isolated from irreversibly-rejected
kidney grafts as effectors against antigens present on lymphoid cells of
donor origin. However, few attempts have been made to evaluate the
susceptibility of donor kidney cells to lysis by GIC. To address this
question, we devised a culture procedure in which GIC as well as
kidney epithelial cells of proximal tubulur origin (PTEC) were selec-
tively expanded. PTEC were characterized by morphology, reactivity
with monoclonal antibodies directed against epithelial membrane anti-
gen and adenosine deaminase complexing protein (ADCP), and by
enzymhistochemistry. GIC were tested for lytic activity against donor
and third party PTEC and against K562 cells and OKT3 hybridoma cells
as NK and T cell targets, respectively. GIC cultured from biopsy
material of a patient with cellular rejection were shown to lyse, in a dose
dependent manner, PTEC of donor origin. The GIC isolated were
functionally characterized as T cells. GIC cultured from a biopsy
specimen of a patient with glomerulonephritis did not show lytic
activity against PTEC. The specificity of GIC cultured from biopsy
specimens of two renal transplant patients with cellular rejections was
further investigated. These GIC lysed donor PTEC and phytohemag-
glutinin-blasts derived from donor spleen cells. Monoclonal antibody
inhibition studies showed that the lytic activity was exerted by T cells
(inhibition by anti-CD3) and that HLA-class I antigens are involved
(inhibition by W6/32, anti-class I). Anti-CD4, CD8, CD2, class II and
leukocyte function associated antigen-I antibodies had no effect. These
results demonstrate that kidney epithelial cells of proximal tubulus
origin are susceptible to lysis by GIC. We therefore suggest that PTEC
may be an important target for the efferent cellular immune response
during rejection after renal allotransplantation.
Induction of antibody.dependent cellular cytotoxicity against endothe-
hal cells by renal transplantation. A.M.M, Miltenburg, M.E. Meyer-
Paape, J.J. Weening, M.R. Daha, L.A. van Es, F.J. van der Woude,
Departments of Nephrology and Pathology, University Hospital, Lei-
den, The Netherlands. Endothelial cells (EC) constitute the primary
interface between a vascularized organ graft and the circulation of its
recipient, and therefore form the most accessible site for graft injury.
Using the serum of a renal transplant patient who had experienced a
severe vascular rejection episode after receiving a HLA-identical
kidney graft from a living related donor, antibody-dependent cellular
cytotoxicity (ADCC) against human umbilical vein EC was detected.
This reactivity was absent in serum obtained before transplantation. We
characterized the ADCC-inducing substance present in the post-trans-
plantation sera by gel filtration studies, protein A absorption, pepsin
digestion experiments and incubation with subclass-specific monoclo-
nal antibodies. The antibodies that were able to bind to EC and induce
ADCC were predominantly of the lgG I subclass. The specificity of the
anti-EC serum was shown in panel studies using EC-lines obtained from
different individuals, and polymorphism in ADCC reactivity could be
demonstrated. In order to investigate the clinical relevance and inci-
dence of anti-EC ADCC, we examined sera of nine additional renal
transplant patients who underwent a renal biopsy to diagnose rejection.
Sera of two of these patients were found positive in the ADCC assay
whereas 20 normal serum donors were negative. Donor monocytes did
not selectively absorb the anti-EC antibodies and no staining of
peritubular capillaries in standard immunofluorescence tests on kidney
tissue slides occurred, indicating that anti-EC ADCC was not a result of
classical anti-endothelial-monocyte (EM) antibodies. Furthermore, an-
ti-EM sera did not induce ADCC of EC. The effector cell responsible
for EC-lysis in the ADCC assay was demonstrated to be of natural
killer/killer (NK/K) cell origin. These findings support the idea that
IgGI antibodies directed against polymorphic non-HLA, non-EM anti-
gens on EC can be induced by renal transplantation. These antibodies
may induce ADCC of EC via Fc interaction with NK/K cells.
Selective reduction of ADPase activity in the glomerular basement
membrane of the rat kidney causes increased intraglomerular thrombosis.
K, Poelstra, M.J. Hardonk, W.W. Bakker, Department of Pathology,
University of Groningen, The Netherlands. Recently nucleoside poly-
phosphatase activity was demonstrated cytochemically at the ultra-
structural level in the rat kidney. Various substrates including UDP,
GDP, ITP and ADP could be used to demonstrate the respective
phosphatase activities in the glomerular capillary wall. Since experi-
mental inactivation of this enzyme system in vivo, that is, by treatment
with adriamycin (ADR) resulted in increased sensitivity for intraglo-
merular thrombosis as demonstrated experimentally by alternate kid-
ney perfusion with platelets and ADP, it was suggested that glomerular
ADPase may subserve an antithrombotic function. Since such an
antithrombotic function would be based on degrading of ADP by
glomerular ADPase of the intact capillary wall, it should be possible to
induce platelet aggregation in the intact kidney when excess of a
competitive substrate, for instance UDP, is supplemented to the
perfusate. After perfusion of the kidney to remove the blood, standard
alternate ex vivo perfusion with 4 ml endotoxin (I sg/ml in saline), I ml
ADP (10 ig/ml), 4 ml human platelet rich plasma (PRP; 2.7 x l0
platelets ml), I ml ADP (10 sg/ml) and 4 ml human PRP was
performed on kidneys of untreated (N = 5) and ADR treated rats (N =
6; 7.5 mg/kg body wt, i.v. 48 hr before the perfusion). Alternate cx vivo
perfusion was also performed with the addition of 100 sg/ml UDP to the
ADP solution of normal (N = 5) and ADR treated rats (N = 5). Kidney
perfusion with UDP alone in the perfusate was also done in untreated
(N = 4) and ADR treated rats (N = 4). Platelet aggregation was
semiquantitatively evaluated at the light microscopical level using
standard methods in three plastic embedded sections of each perfused
kidney. The results expressed as mean percentages of scored glomeruli
with platelet aggregation can be summarized as follows:
Substrate in
kidney
perfusion
Normal
rats P
ADR
treated
rats P
ADP 24% NS 54% 0.0I
ADP + UDP 69% 0.00l 79% 0.00l
UDP 26% NS 29% NS
Mean percent as indicated (Wilcoxon) compared to ADP in normal
kidneys
It is clear that addition of the competitive substrate UDP leads to
impairment of the antithrombotic potential of glomeruhi in both normal
and ADR treated rats due to selective elimination of glomerular ADPase
activity. Since this effect could also be achieved by other competitive
substrates, that is, ITP and GDP using the present system, it is
concluded that glomerular ADPase plays a significant role as an
antithrombotic mechanism in the glomerulus of the rat kidney.
Comparative effects of cholestyramine and the 11MG CoA reductase
inhibitor simvastatin on hipoprotein profile in the hyperhipidemia of
nephrotic syndrome (NS). A.J. Rabelink, R. Hené, D. Erkelens, H.A.
Koomans, Departments of Nephrology and Internal Medicine, Univer-
sity Hospital, Utrecht, The Netherlands. Hyperlipidemia is a common
feature of NS. In prolonged unremitting NS, hyperlipidemia may be
present for many years. Lipoprotein profile and autopsy studies make it
likely that this hyperlipidemia accelerates atherosclerosis. In a cross-
over study we compared the safety, tolerability and efficacy of six
weeks of simvastatin (20 mg b.i.d.) and six weeks of cholestyramine (8
g b.i.d) in eight patients with hyperlipidemia due to unremitting ne-
phrotic syndrome.
Results (sD) Placebo Simvastatin
Tot. chol. 10.0 2.0 6.4 l.6
mmol/liter
LDL-chol. 7.0 1.7 4.3 1.6'
mmol/liter
HDL-chol. 1.0 0.3 1.2 0.3
mmol/liter
Triglycer. 4.5 l.6 2.7 l.2
mmol/liter
Apo-A-l l.97 0.31 2.17 0.34c
g/liter
Apo-B l.60 0.42 1.12 052ad
g/liter
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Placebo Cholestyramine
Tot. chol. 10.5 2.6 9.4 1.9
mmol/liter
LDL-chol. 7.3 2.6 5.9 2.2C
mmol/!iter
HDL-chol. 0.9 0.2 1.1 0.4
mmol/liter
Triglycer. 4.3 1.6 5.2 4.0
mmol/liter
Apo-A-L 1.98 0.30 2.06 0.30
giliter
Apo-B 1.67 0.38 1.56 0.35
giliter
a P <0.01, b P <0.05 simvastatin vs. cholestyramine; P <0.05, d p
<0.01 vs. placebo.
Conclusions: I) Simvastatin is effective in reducing cholesterol and
triglycerides, and improved the LDL-to-HDL ratio in NS. 2) Simvasta-
tin is more effective in the treatment of nephrotic hyperlipidemia than
cholestyramine. 3) Simvastatin was well tolerated and no side effects
were noticed in this short term study.
Atrial natriuretic peptide (ANP) is not a major determinant of the renal
response to head-out water immersion. A,J. Rabelink, H.A. Koomans,
CA. Gaillard, E.J. Dorhout Mees, Department of Nephrology, Uni-
versity Hospital, Utrecht, The Netherlands. In order to appraise the
role of ANP in the natriuresis induced by head-out water immersion
(HO!), during clearance studies we compared the effect of 3 hours HO!
with an equally natriuretic 3 hours infusion of ANP (0.01 sg
kg' min' human ANP 99-126) in seven healthy individuals taking a
100 mmol sodium diet. Since we found previously that converting
enzyme inhibition with enalapril inhibits the natriuresis after ANP,
studies were also performed during enalapril (20 mg b.i.d.). The main
findings were: 1) HOE induced a similar natriuresis as ANP infusion
with an about five times smaller rise in plasma ANP; 2) while both
maneuvers tended to increase glomerular filtration rate (inulin clear-
ance), effective renal plasma flow (PAH clearance) was increased by
HOL and decreased by ANP; 3) maximal free water clearance was
increased and fractional lithium reabsorption decreased by HO!,
whereas ANP had no effect on these variables but increased minimal
urine osmolality; 4) in contrast to earlier studies with higher dosages,
ANP reduced potassium excretion. HOI, however caused a initial
kaliuresis; 5) enalapril virtually abolished the natriuresis after ANP, but
did not affect natriuresis after HO!, even though during enalapril HO!
caused a large fall in blood pressure (--15 mm Hg). These data indicate
that the mechanism of natriuresis of these two equally natriuretic
maneuvers is essentially different, and that ANP plays no major role in
the natriuresis of HOI. In addition, in physiological concentrations
ANP may act preferentially in the distal nephron, causing natriuresis
and potassium retention.
Successful intravenous 1 (OH) vitamin D3 therapy for secondary
hyperparathyroidism in hemodialysis patients. P. Rademaker, C.
Henkens, W. Geerlings, G.v.d. Hem, H. Sluiter, S. Meyer, University
Hospital, Groningen, The Netherlands. Recently treatment with intra-
venous I (OH) vitamin D3 [!vD3] was described as a possible alternative
to parathyroidectomy [PTx] in the treatment of secondary hyperpara-
thyroidism in haemodialysis patients (pts). To evaluate the efficacy of
this vitamin D3 therapy we compared our first results with !vD3
treatment with those obtained in fourteen patients who underwent PTx
as historical controls. Seven pts with grossly elevated PTH levels, in
spite of dietary measures and administration of oral phosphate binders
and/of vitamin D, were treated for 16 6 months with !vD (Ito 4 g
after dialysis). Serum Ca, P, alkaline phosphatase [A.Ph.] and intact
amino(N)-terminal PTH levels (normal values I to II pmol/Iiter) were
determined before and six months after PTx and at the start, at six
months and at the end of follow up of !vD3 treatment. Biochemical data
(mean SEM) are given in the Table.
Ca P A.Ph.
Militer
PTH
p,nol/litermmol/liter
PTx
Before 2.77 0.07a 1.68 0.20 328 68 101 ll
6 months 2.45 0.06" 1.39 0.14 184 51k' 33 23b
lvD3
Before 2.51 0.04 2.2! 0.26 430 88 60 12
6 months 2.53 0.07 2.30 0.37 227 33b 30 6
16 months 2.60 0.05 2.21 0.06 173 32" 23 3b
a P < 0.05 PTx vs. IvD1
b p < 0.05 6 or 16 months vs. before.
The falls in A.Ph. and PTH caused by both treatments were not
significantly different. In one patient, in whom subtraction-scintigraphy
for parathyroid localization before and after 22 months of IvD3 treat-
ment was performed, a decrease in parathyroid activity was found.
Conclusions: 1.) !vD3 is an effective primary treatment for secondary
hyperparathyroidism in renal failure patients. 2.) The effect of !vD3 on
PTH levels appears to be independent of significant changes in Ca and
P levels.
Tubular dysfunction in proliferative glomerulonephritis in SLE. E.J.
ter Borg, P.E. de Jong, S. Meyer, C.G.M. Kallenberg, University
Hospital, Groningen, The Netherlands. Though glomeru!ar pathology
predominates. tubulointerstitial changes probably also play a role in
lowering GFR in active lupus nephntis. We prospectively studied the
tubular function during exacerbations of proliferative glomerulonephri-
us in SLE. Data are available prior to and during exacerbation (N = 7),
or during and after exacerbation (remission) (N = 9). Serum comple-
ment C3 and C4 (mg/liter), GFR, ERPF (mI/mm), FF (%), fractional
excretion (FE) of /32-microglobulin (2m, % x 100), FE of DMSA (%),
proteinuria (prot.. g/day) and urinary LDH (urin.LDH, U/mmol creat)
were measured. Therapy during exacerbation consisted of prednisolone
and cyclophosfamide in all cases.
Prior to During During After
N =7 N =9
C3 72 15 38 isa 42 14 82 2&
C4 14±4 10±3 11±5 l6±6a
GFR 95 22 47 23 60 34 88 4l
ERPF 539 160 394 188 462 191 416 133
FF 18.1 3.1 11.6 4.2a 12.9 4.2 20.6 3.6a
FE /32-m 0.15 0.16 0.32 0.l0a 0.33 0.11 0.12 0.l5
FE DMSA 11.1 1.5 18.7 6.8a 17.3 2.6 11.9 2.5
Proteinuria 1.8 2.4 5.3 33a 3.5 2.! 1.6 l.8a
Urinary LDH 7.0 5. 10.5 10.9 4.9 3.4 2.5 0.8a
a P 0.05 versus value in the period before.
Titers of anti-ds DNA rose (P  0.1) during exacerbation in all but one
patient, and fell (P  0.05) after exacerbation in all cases. No consistent
pattern of serum potassium, urinary alkaline phosphatase and urinary
g-glutamyl-transpeptidase concentrations was found. Since fractional
excretion (FE) of f32-m and DMSA can be used as a marker for tubular
function, the rise in these parameters during exacerbation, and the fall
to control values during remission indicate that tubular dysfunction
frequently is present during proliferative glomerulonephritis in SLE; its
contribution to lowering GFR is difficult to assess.
Experimental and clinical evidence for cross reactivity of anti-DNA
antibodies with heparan sulphate in SLE nephritis. R. Termaat, K.
Brinkman, R. Smeenk, L.v.d. Heuvel, J. Veerkamp, J. Nossent, A.
Swaak, P. Faaher, K. Assmann, J. Berden, University of Nijmegen,
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CLB Amsterdam, The Netherlands. We have shown previously that
polyclonal anti-DNA antibodies can crossreact with heparan sulphate
(HS), which is a constituent of the GBM. Sixteen out of 42 monoclonal
anti-DNA antibodies (MoAb) reacted in ELISA with purified HS.
Heparan sulphate proteoglycan (HSPG), which carries HS as its side
chains, was isolated from human glomeruli or GBM. In the HSPG-
ELISA 12 MoAb were positive whereas in Western blots 4 MoAb
showed binding to intact HSPG but not to HSPG-core protein after
removal of HS. Subsequently we isolated OHM-loops (GBM-L) from
human and rat glomeruli. Ultrastructurally we found a strong binding of
cationic ferritin (CaF), indicating that the anionic sites of the GBM were
well preserved. With indirect immunofluorescence 7 of the 42 MoAb
showed a fine granular staining along the GBM-L. Heparitinase treat-
ment of GBM-L diminished but did not completely prevent binding of
either CaF or MoAb. Preincubation of GBM-L with CaF almost
completely inhibited the subsequent binding of MoAb. Binding of
MoAb to GBM-L as well as to HS and HSPG could be inhibited by
DNA. Some MoAb showed a positive GBM-L staining although they
did not react with HS or HSPG. These results demonstrate that
monoclonal anti-DNA antibodies can bind directly to HS and to other
not yet identified anionic sites in the GBM. To investigate the clinical
significance of cross reactivity of anti-DNA antibodies with HS. sera
from SLE patients with or without nephritis were studied longitudinally
in a HS and DNA-ELISA (6 to 16 serum samples per patient in 10 SLE
patients). In five Out of five episodes of SLE nephritis we found anti-HS
reactivity in the serum before the onset of the nephritis. in four
non-renal exacerbations anti-HS reactivity was found in only one
episode. In three patients who remained clinically stable, none of the
serum samples showed anti-HS reactivity. These data suggest an
association between onset of SLE nephritis and occurrence of a
subpopulation of anti-DNA antibodies which cross reacts with heparan
sulphate.
Hypokalemic alkalosis with polyuria and renal salt loss responding to
atenolol (A) in a 78-year-old patient. R. Verberckmoes, E. Cox, B. Van
Damme, P. Michielsen, Dienst Nefrologie, U.Z. Gasthuisberg, Leu-
yen, Belgium. This patient was admitted fora syndrome of recent origin
consisting of polydipsia, ADH resistant polyuria, renal salt wasting,
hyponatremia, potassium- and chloride-resistant metabolic alkalosis,
hypouricemia, proteinuria, high PRA, angiotensin and aldosterone
levels. No arguments for pathology of adrenals or hypophysis were
found. Vomiting, abuse of diuretics or laxatives were excluded. No
hyperplasia of the juxtaglomerular apparatus were found on renal
biopsy. Striking retention of Nat, K and C1 and weight gain of 5 kg
followed the institution of a treatment with A (50 mg/day) which also
decreased proteinuria, normalized uricemia, PRA, angiotensin and
aldosterone. Repeated interruption of the treatment with A was fol-
lowed by recurrence of the syndrome which each time disappeared
upon reinstitution of the treatment. A clearance study with constant
infusion was done to examine the acute effects of A (100 mg):
Before A 2—4 hours after A
BP mm Hg 190/100 190/85
Heart rate min' 80 62
Urine flow mI/mm 8.7 1.8
Inulin clearance mI/mm 67 52
PAH clearance mI/mm 216 189
FF% 31 27
FeNa % 8.4 2.1
Fec1-% 11.6 2.6
CK/CIflUjfl % 67 48
CLI/CIfllfl % 54 34
Cardiac index measured before and 3 hours after A (50 mg) was 2.2 and
2.0 I/mm . m2, respectively. Although this clinical picture may resem-
ble Bartter's syndrome, several aspects, in particular the striking
response to A, are uncommon in this syndrome. The pathophysiology
in this patient is best explained by glomerular hyperfiltration causing
increased distal fluid delivery. A probably corrects the syndrome by its
influence on cardiac output. The etiology is speculative.
Continuous arterio-venous hemodiafiltration (CAVHD): Determinants
of solute transport. H.H. Vincent, F.J. van Ittersum, M.A.D.H. Scha-
lekamp, Department of Internal Medicine I, University Hospital,
Rotterdam, The Netherlands. In CAVH membrane permeability index
(MI. mt/hr. mm Hg), defined as the ratio of ultrafiltration rate (UF) and
net transmembrane pressure (TMP), shows a predictable decline with
time, most likely due to coating of the membrane with protein. As a
result, with CAVH alone, solute transport may be inadequate for
correction of the uremic state. We therefore routinely perform CAVHD
in which dialysate is run counter currently at a flow rate (QD) up to 3
liter/hr. TMP and hence UF rate are not affected. In order to determine
the efficiency of CAVHD we measured total clearance from UF, QD
and the ratio of plasma and spent dialysate/ultrafiltrate solute concen-
tration (SatD). When UF rate was low for TMP (low Ml value),
diffusive transport was likewise depressed. With blood flows (QB) 100
to 200 mI/mm and Ml >3 mI/hr mm Hg, SatD mainly depended on MI,
QD and UF rate. For practical purposes, SatD can be predicted from
the ratio QD/UF. Mean (SEM) values for urea, creatinine and phos-
phate are given in the Table:
QD/UF SatD urea % SatD creat % SatD P04 %
0.5 101.3 (0.8) 98.4 (0.6) 95.7 (1.7)
1.0 100.6(1.0) 95.5(1.2) 92.6(2.2)
2.0 95.0 (0.9) 87.3 (1.7) 79.6 (2.3)
3.0 87.7(1.0) 78.4(1.6) 68.9(1.9)
4.0 80.8(1.4) 71.8(2.7) 60.4(2.1)
5.0 74.0 (1.9) 64.1 (2.0) 54.0 (2.7)
N = 20; data obtained with the AN-69 0.43 m2 plate filter
With capillary filters the rate of decline of MI with time proved slower
than with plate filters. The relation between SatD and QD/UF was,
however, similar. These empiric data may be used to adjust QD to the
required rate of solute clearance. Furthermore, when blood chemistry,
QB. QD, MI and UF are all taken into account, the data provide a basis
for the development and testing of a model of the kinetics of diffusive
transport, which might be used to optimize the technique of CAVHD.
Cyclosporine nephrotoxicity: Pitfalls in the estimation of flow and
filtration by clearance techniques. G.J. Wenting, H.H. Vincent, D.J.
Versluis, F.H.M. Derkx, W. Weimar, University Hospital, Rotterdam,
The Netherlands. To explore the limitations of serum creatinine (SCr)
and creatinine clearance (Car) as measures of glomerular filtration rate
(GFR) during cyclosporine therapy (CsA) and to determine whether
renal vasodilatation underlies the improvement of renal function after
stopping CsA, 25 renal cadaveric transplant recipients were studied
throughout elective conversion from CsA to azathioprine (AZA). They
had been taken CsA for at least one year and renal function before
conversion was compromised but stable. After conversion Se,. fell
markedly (185 6 to 134 4 mol/liter, mean SEM, P < 0.01) but
changes in GFR (clearance of '25I-iothalamate, C101) were modest (+ 12
4%, P < 0.05). The rise of Cr was 2.5 times greater than the rise of
C101. Effective renal plasma flow (ERPF, clearance of '311-iodohippu-
rate) rose by 25 6% (P < 0.01). Provided that C101 represents true
GFR, our data suggest that the fraction of creatinine cleared by tubular
secretion did increase markedly after conversion. When this also holds
for the tubular secretion of iodohippurate, there is the possibility that
the rise in ERPF after the switch to AZA reflects more a change in
extraction efficiency than a rise in true renal blood flow. Practical
consequences of these findings are: I.) an erroneous overestimation of
the real improvement of GFR after stopping CsA when S. and Cr are
used as criteria; 2.) uncertainty whether CsA-induced renal vasocon-
striction is reversible after prolonged exposure to the drug.
